Your Off-Target Confirmation Partner — From Coordinates to Report
A Frictionless End-To-End Service
You define the targets. We handle the rest. LockSeq runs as a complete service — probe design, library prep, sequencing, analysis, and reporting — delivered in 15 business days. No instrument investment. No bioinformatics overhead.
FDA Now Requires Orthogonal Off-Target Assessment
The FDA's April 2026 Draft Guidance on genome editing safety explicitly calls for orthogonal confirmation methods — independent of the nomination assay — for IND-enabling submissions.
As panel size grows, maintaining sensitivity and complete target coverage becomes increasingly challenging. Missing sites are not just data gaps—they are genomic blind spots that can translate into development delays and regulatory risk.
LockSeq is purpose-built for this requirement.
What's Included in Every LockSeq Study
Countagen provides LockSeq as an end-to-end service model designed to eliminate the operational and infrastructure barriers of high-plex gene-editing validation. Focus on your therapeutic discovery while we deliver the sequence-level truth.
.png?width=2000&height=448&name=High-Level%20Workflow%20(3).png "High-Level Workflow")
We review your edit design, gRNA sequences, and nominated off-target coordinates. Where needed, we can supplement with in silico nomination. Turnaround: Usually within 24 hours from first contact to project specification.
We design padlock probes for all your on- and off-target loci — up to 1,000+ sites per reaction. Probes are validated in silico before synthesis.
Mix-and-match of new targets across development stages without panel redesign.
LockSeq library preparation and sequencing are performed in our Stockholm laboratory. Illumina and Oxford Nanopore platforms confirmed.
You receive a UMI-corrected variant allele frequency report with indel profiling, coverage uniformity charts, and raw data (FASTQ + BAM). Standard turnaround: 15 business days from DNA receipt.
Transparent Starting Points
LockSeq service pricing scales with panel size and sample number.
Request a quote for your specific panel configuration. Most projects are scoped within 24 hours.
Why Choose LockSeq
High-Confidence Edit Detection
LockSeq uses gap-fill ligation to capture target molecules prior to amplification. UMI-based consensus sequencing suppresses technical errors, enabling confident detection of edits down to 0.1% VAF across panels exceeding 1,000 targets.
Fewer Dropouts. Better Coverage.
LockSeq is designed to minimize target dropout in highly multiplexed workflows. By reducing assay complexity and potential molecular interactions, the platform improves target representation and supports more complete genomic characterization across large panels.
One Workflow. Any Scale.
Reconfigure targets without assay redesign. LockSeq supports everything from single-site confirmation to >1,000-plex off-target characterization in a single workflow, with demonstrated compatibility across Illumina and ONT.
Trusted by Leading Gene Editing Research Programs
